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Although the PPARg agonist troglitazone has been shown to induce growth inhibition of hepatocellular carcinoma (HCC) cells at high
concentration, this study indicates troglitazone does not significantly inhibit the growth of HCC cells at clinically achievable
concentrations (1–10mM), and this lack of activity could not be improved by the addition of 9-cis-retinoic acid. Furthermore, no
synergistic effect was found between troglitazone and cytotoxic anticancer agents.
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The peroxisome proliferator-activated receptor g (PPARg), a
member of the nuclear hormone receptor superfamily, functions
as a ligand-dependent transcription factor and plays an important
role in several signalling pathways, including lipid metabolism,
glucose homeostasis, and inflammation (Kersten et al, 2000).
Heterodimerisation of PPARg and retinoid X receptor (RXR) is
required for binding to specific DNA response elements of target
genes. Binding with either PPARg or RXR ligands will elicit
transcriptional activation of the target genes (Vanecq and Latruffe,
1999; Corton et al, 2000). Synergistic activation of downstream
genes may occur when both ligands are present (Kliewer et al,
1992; Desvergene and Wahli, 1999). The thiazolidinediones were
found to be specific agonists of PPARg, with EC50 less than 1mM
(Lehmann et al, 1995). The potency of the thiazolidinediones in
activating PPARg in vitro was found to correlate closely with their
lipid- and glucose-lowering activity in vitro (Berger et al, 1996;
Willson et al, 2001). Troglitazone, a thiazolidinedione derivative,
has been demonstrated to induce adipocyte proliferation and
differentiation with the concentrations of 0.5–5mM (Tafuri, 1996).
The anticancer activity of PPARg agonists was first demonstrated
in a liposarcoma model. Thiazolidinedione derivatives induced
terminal differentiation of liposarcoma cells (Tontonoz et al, 1997;
Demetri et al, 1999; Tsibris et al, 1999). Subsequent studies indicated
that PPARg agonists, at concentrations of 1–10mM,m a yi n d u c e
growth inhibition in a variety of cancers, including cancers of breast,
colon, and prostate (Kubota et al, 1998; Sarraf et al, 1998; Mehta et al,
2000). In addition to promotion of cell differentiation, the PPARg
agonists-induced growth inhibition may involve various mechanisms
such as induction of cell cycle arrest, inhibition of DNA synthesis, and
increase of cancer cell necrosis and apoptosis. Moreover, synergistic
or additive effects of growth inhibition between PPARg and RXRa
agonists have been found in liposarcoma and breast cancer cells.
Clinical trials exploring the feasibility of using PPARg agonists in the
treatment of human cancers are underway (Koeffler, 2003).
Recent studies have demonstrated that PPARg agonists may
induce growth inhibition in hepatocellular carcinoma (HCC) cells
in a dose- and time-dependent manner (Koga et al, 2001; Rumi
et al, 2001; Yoshizawa et al, 2002). Troglitazone, a thiazolidine-
dione derivative, enhanced the expression of the cyclin-dependent
kinase inhibitors p21
WAF1/Cip1 and p27
Kip1 and resulted in cell cycle
arrest at G0/G1 phase. PPARg agonists may also augment Fas-
mediated apoptosis of HCC cells induced by tumour necrosis
factor a (Okano et al, 2002). However, these effects were observed
at relatively high concentrations (20–50mM) of troglitazone, while
the clinically achievable concentrations are around 2–5mM (Berger
et al, 1996; Tafuri, 1996; Spencer and Markham, 1997; Willson et al,
2001). Therefore, the utility of PPARg agonists for the treatment of
HCC remained undetermined.
The current study was designed to address the following
questions: (1) whether troglitazone alone, at clinically achievable
concentrations, may be active against HCC cells; (2) whether
troglitazone has a synergistic effect with RXRa agonists on growth
inhibition of HCC cells; (3) whether the effects of troglitazone and
RXRa agonists correlate with the expression of PPARg and RXRa
in HCC cells; and (4) whether troglitazone, at clinically achievable
concentrations, may enhance the cytotoxic effects of major
chemotherapeutic agents.
MATERIALS AND METHODS
Cell culture and reagents
A panel of HCC cell lines was tested in this study: Hep3B, HepG2,
SNU-449 (Park et al, 1995), (purchased from ATCC), PLC-5, Huh-7
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y(Nakabayashi et al, 1982), SK-hep1 (Fogh et al, 1977), HA-59T
(Wuu et al, 1990) (gifts of Professor Ming-Yang Lai, Graduate
Institute of Medicine, College of Medicine, National Taiwan
University). MCF-7 (purchased from ATCC), a breast cancer cell
line characterised by expression of RXRa and 9-cis retinoic acid (9-
cis RA) growth inhibition, was used as positive control for RXRa
expression and 9-cis-RA-induced cytotoxicity in this study
(Gottardis et al, 1996). The HCC cells and MCF-7 were cultured
in Dulbecco’s modified Eagle’s medium supplemented with 10%
foetal bovine serum, 100U/ml penicillin, and 100mg/ml strepto-
mycin, and maintained in a humidified incubator of 5% CO2 in air
at 371C.
Troglitazone was purchased from Cayman Chemical (Ann
Arbor, MI, USA) and 9-cis-RA was purchased from Sigma (St
Louis, MO, USA). We used 9-cis retinoic acid in our study because
in earlier studies it has been demonstrated to have synergistic
activity with PPARg agonists in regulation of lipid metabolism and
in a leiomyosarcoma model. Both troglitazone and 9-cis-RA were
prepared in dimethyl suphoxide (DMSO) for cytotoxicity assay.
The final concentration of DMSO was controlled at below 0.5%.
The cytotoxic agents were provided by the following companies:
gemcitabine, Eli Lilly; irinotecan, Rhone–Poulenc–Rorer; cispla-
tin, David Bull Laboratories; paclitaxel, Bristol-Myers-Squibb.
Polyclonal mouse antibodies detecting PPARg and rabbit anti-
bodies detecting RXRa were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA, USA). Monoclonal antibody detecting
proliferating cell nuclear antigen (PCNA) was purchased from
Chemicon (Temecula, CA, USA). The anti-PPARg antibody we
used in this study was mapped to the N-terminal of PPARg
(sc-7196, Santa Cruz, CA, USA). No cross reaction with other
PPAR isoforms has been reported by the manufacturer. The
dilution of antibodies was 1:1000 for primary antibodies and
1:2500 for secondary antibodies.
Extraction of nuclear proteins and Western blot analysis
The methods of nuclear protein extraction and Western blot
analysis have been described previously (Chuang et al, 2002).
Briefly, cells (3–5 10
6) were scraped from culture dishes, washed
with iced phosphate-buffered saline, resuspended in 1ml of buffer
A (1.5mM MgCl2,1 0m M KCl, 0.5mM dithiothreitol, 0.2mM PMSF,
1% Nonidet P-40, 10mM HEPES, pH 7.9), and incubated for 10min
at 41C. The cells were then centrifuged at 1500rpm for 2min at 41C
and the pellet was resuspended in 0.1ml of buffer B (25% glycerol,
420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM dithiothreitol,
0.2mM PMSF, 20mM HEPES, pH 7.9) and incubated for 20min at
41C. The cell suspension was then centrifuged at 14000rpm for
2min at 41C, and the supernatant was collected for protein
quantification using a modified Lowry’s method. The supernatant
was stored in aliquots at  701C. A measure of 30mg of protein was
deposited in each lane on the blot. The proteins were separated by
SDS–PAGE and transferred to nitrocellulose membranes. The
membranes were incubated with the appropriate primary anti-
bodies, followed by incubation with horseradish peroxidase-
conjugated secondary antibodies and a chemiluminescence agent
(Santa Cruz). The proteins were then detected by roentgeno-
graphy.
For each study at least three independent experiments, including
independent cultures, protein collection and quantification, were
done and separate blots were done to detect the expression of
PPARg and RXRa. The most representative figures were shown.
Cytotoxicity assay
Cytotoxicity was determined by a tetrazolium-based semiauto-
mated colorimetric assay (MTT assay) (Mosmann, 1983). Three
independent experiments of each cytotoxicity test have been done
and the results were the mean of the three experiments. For each
experiment at least three replicates were done. Cells were plated in
96-well plates 3–4 10
3well
 1) and incubated overnight. The
drugs were added to the wells and the percentage of surviving cells
was measured by MTT assay after continuous drug exposure for
72h. Concurrent drug exposure was used to evaluate the
combination effect of troglitazone with 9-cis-RA and troglitazone
with four cytotoxic agents (gemcitabine, cisplatin, paclitaxel and
irinotecan) that have different mechanisms of cytotoxicity. The
IC50 of individual cell lines was calculated by using a linear
regression based on the MTT assay results. The drug concentration
corresponding to 50% inhibition of control was designated as
IC50.
RESULTS
Expression of PPARc and RXRa and single-agent activity
of troglitazone
The nuclear expression of PPARg and RXRa and the growth
inhibitory effect of troglitazone on HCC cells are shown in Figure 1.
All tested HCC cell lines expressed various levels of PPARg and
RXRa constitutively (Figure 1A). Troglitazone, up to 10mM, had no
significant growth inhibitory activity on any of the HCC cell lines.
Growth inhibition was noted at concentration more than 20mM,
and the degree of inhibition did not correlate with the expression
levels of PPARg or RXRa (Figure 1B).
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Figure 1 (A) Western blot analysis of PPARg and RXRa expression in
nuclear protein lysate of HCC cells. All tested HCC cell lines expressed
various levels of PPARg and RXRa constitutively. PCNA staining was used
as loading control. (B) Growth inhibition of HCC cells induced by
troglitazone determined by MTT assay. Growth inhibition was noted at
concentration more than 20mM, and the degree of inhibition did not
correlate with the expression levels of PPARg or RXRa.
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Addition of 10mM of 9-cis-RA caused 60% growth inhibition of
MCF-7 cells but had no significant growth inhibitory effects on any
of the HCC cells and did not affect the sensitivity of HCC cells to
troglitazone (Figure 2).
Combination activity of troglitazone and anticancer agents
The IC50 of the four cytotoxic agents in three HCC cell lines, with
and without the addition of 10mM of troglitazone, is listed in
Table 1. The addition of troglitazone did not change the sensitivity
of HCC cells toward any of the cytotoxic drugs.
DISCUSSION
This study indicates that troglitazone does not significantly inhibit
the growth of HCC cells at clinically achievable concentrations,
and this lack of activity could not be improved by the addition of
9-cis-RA. Furthermore, no synergistic effect was found between
troglitazone and four representative anticancer agents.
There was no apparent correlation between the degree of growth
inhibition by troglitazone and the level of PPARg or RXRa
expression in our study. No correlation of the sensitivity of HCC
cells to troglitazone with expression levels of PPARg has been
noted (Koga et al, 2001; Rumi et al, 2001; Okano et al, 2002).
Similarly, previous studies for the sensitivity of cancer cells to
retinoids have demonstrated that the growth inhibitory effects of
retinoids did not correlate to the expression levels of different
isoforms of retinoic acid receptors and RXRs (van der Leede et al,
1993). Other factors, including the levels of ‘free’ RXRa that is
available for PPARg-RXRa interaction, the content of other nuclear
receptors, and the possible interaction among nuclear coactivators
and corepressors, may play an important role in determining the
sensitivity of cancer cells to the nuclear receptor agonists (Torchia
et al, 1998).
Although troglitazone and other thiazolidinediones are con-
sidered specific PPARg agonists, several lines of evidence suggest
that the growth inhibition of HCC cells induced by high
concentrations of troglitazone may occur through PPARg-
independent mechanisms. First, thiazolidinediones induce differentia-
tion of adipose tissue and insulin sensitization at submicromolar
levels and these effects are closely related to their binding affinity
to PPARg receptor (Lehmann et al, 1995; Goldstein, 2002). On the
other hand, concentrations of troglitazone and other thiazolidine-
diones required to induce significant anticancer effect are usually
10mM or higher. Besides, no evident relationship between antic-
ancer efficacy and the expression of PPARg in cancer cells or the
binding affinity of thiazolidinediones to PPARg has been
established. Second, addition of RXRa agonist may also improve
the insulin-sensitising effect of thiazolidinediones by enhancing
the formation of PPARg–RXRa heterodimer (Mukherjee et al,
1997). This synergistic effect has also been found in liposarcoma
and breast cancer cell lines but not in the present study, in spite of
the constitutive expression of PPARg and RXRa in the nuclei of
HCC cells. Third, inhibition of cell growth by troglitazone through
PPARg-independent mechanisms has also been demonstrated in
PPARg
 /  embryonal stem cells (Palakurthi et al, 2001). Trogli-
tazone may inactivate the eukaryotic initiation factor 2 (eIF2)
and abrogate the expression of G1 cyclins, thus resulting in cell
cycle arrest at G1–S transition. Because the concentration of
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Figure 2 Growth inhibition of HCC cells induced by troglitazone with or without the addition of 10mM of 9-cis-RA. Addition of 9-cis-RA did not affect the
sensitivity of HCC cells to troglitazone.
Table 1 IC50 (mM) of cytotoxic agents with or without troglitazone in
HepG2 and PLC cell lines
HepG2 PLC-5
Cisplatin 5.170.6 52.271.5
Cisplatin+T 5.071.4 55.571.3
Gemcitabine 0.6570.40 47.374.8
Gemcitabine+T 0.8770.31 43.378.4
Paclitaxel 0.9570.19 6.971.5
Paclitaxel+T 0.7970.21 5.771.2
Irinotecan 37.778.2 427.5766.8
Irinotecan+T 36.477.3 452.27122.2
T¼troglitazone 10mM. The IC50 of individual cell lines was calculated by using a
linear regression based on the MTT assay results. The drug concentration
corresponding to 50% inhibition of control was designated as IC50.
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significantly higher than the clinically achievable serum concen-
tration (2–5mM), the clinical usefulness of troglitazone alone as an
anticancer agent for HCC appears to be limited.
Troglitazone has also been demonstrated to induce cell cycle
arrest through increased expression of the cyclin-dependent kinase
inhibitors p21
WAF1/Cip1, p27
Kip1, and p18
INK4c. Cell cycle modula-
tion has been intensely investigated as a novel way to induce
sensitisation to chemotherapeutic drugs as well as to inhibit cancer
cell growth (Senderowicz and Sausville, 2000; Sherr, 2000).
However, the concentration of troglitazone necessary to induce
this effect is much higher than that achievable clinically. Four
major anticancer agents were tested in this study for their effect in
combination with troglitazone. The lack of synergistic activity
between troglitazone and cytotoxic drugs in this study suggests
that troglitazone may not be effective as a biochemical modulator
for HCC.
The reason for the lack of efficacy of troglitazone as a
biochemical modulator for HCC cells remained undetermined.
Most of the HCC cell lines came from patients with surgically
resected tumours. Some cell lines, such as PLC5, have been found
to have integration of hepatitis B viral DNA into the host genome.
The implication of viral DNA integration into host cells on drug
sensitivity is not known, although in vitro data suggested that
expression of hepatitis B viral proteins may increase apoptosis
threshold and resistance to cytotoxic agents of cancer cells (Doong
et al, 1998; Shih et al, 2000).
Nevertheless, the PPARg agonists may have other anticancer
effects. It has been demonstrated that PPARg agonists are potent
inhibitors of angiogenesis (Xin et al, 1999). Rosiglitazone, another
thiazolidinedione derivative, has been shown to inhibit both
primary tumour growth and metastasis (Panigrahy et al, 2002).
The potential mechanisms of action include direct inhibition of
endothelial cell proliferation, decrease of vascular endothelial
growth factor production by tumour cells, and increased activity of
the tissue inhibitor of matrix metalloproteinase (TIMP). Notably,
the concentrations of rosiglitazone that had the strongest
antiproliferative effect on endothelial cells (0.01–1mM) are
clinically achievable. Therefore, it remains a possibility that new
PPARg agonists with novel antitumour mechanisms that are
effective for the treatment of HCC can be developed.
In conclusion, troglitazone, at clinically achievable concentra-
tions, does not appear to be active against HCC cells, either alone
or in combination with 9-cis-RA or chemotherapeutic agents.
Further exploration for new derivatives of PPARg agonists with
better antitumour activity in HCC is needed.
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